Frank Rimerman Advisors LLC Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Frank Rimerman Advisors LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 524 shares of the biopharmaceutical company’s stock after selling 73 shares during the period. Frank Rimerman Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $373,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in REGN. Amundi raised its holdings in Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after acquiring an additional 487,489 shares during the last quarter. Proficio Capital Partners LLC raised its stake in Regeneron Pharmaceuticals by 92,865.3% during the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock valued at $156,284,000 after buying an additional 219,162 shares during the last quarter. Worldquant Millennium Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $127,489,000. KBC Group NV raised its stake in Regeneron Pharmaceuticals by 296.7% during the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after buying an additional 102,198 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $65,180,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 2.0 %

REGN opened at $666.87 on Monday. The firm has a 50-day simple moving average of $694.91 and a two-hundred day simple moving average of $831.18. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company has a market capitalization of $72.91 billion, a PE ratio of 17.42, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the firm earned $11.86 EPS. The business’s revenue was up 10.3% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on REGN. Piper Sandler decreased their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. TD Cowen reduced their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. Citigroup reduced their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Finally, UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.